Belvedere Trading’s INmune Bio INMB Stock Holding History

Belvedere Trading’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16,177	Closed	-$302K	–	530
2021 Q3	$302K	Sell	16,177 -11,791	-42%	-$228K	0.01%	183
2021 Q2	$588K	Buy	+27,968	New	+$377K	0.04%	93

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belvedere Trading's INMB Position: Q4 2021 in Review

Belvedere Trading sold out of INmune Bio (INMB) in Q4 2021, closing a stake of 16,177 shares — an estimated $302K sold.

Belvedere Trading first reported a position in INMB in Q2 2021 and held it in 2 quarters. The position peaked at $588K in Q2 2021. 43 funds tracked by Wall St. Rank hold INMB as of Q4 2021.

Belvedere Trading reported no remaining INmune Bio position as of Q4 2021 after selling out during the quarter.
Belvedere Trading sold 16,177 INmune Bio shares in Q4 2021, an estimated $302K.
Belvedere Trading first reported a position in INmune Bio in Q2 2021 and held it in 2 quarters.
Belvedere Trading's INmune Bio position peaked at $588K in Q2 2021.
43 funds tracked by Wall St. Rank held INmune Bio as of Q4 2021.

Based on Belvedere Trading's 13F filing for Q4 2021, filed 25 Jan 2022.